About Qairnel
We build the foundations for earlier, more effective brain health interventions
Our story
Scientific origins
Qairnel originates from research conducted at the Paris Brain Institute (ICM), on the Pitié-Salpêtrière hospital campus, where our work on disease progression modeling began in 2015. We addressed a fundamental challenge in neuroscience: modeling long-term disease trajectories from short-term heterogeneous patient data. This led to new mathematical foundations for disease progression modeling, patented in 2016 and published in 2017 in the Journal of Machine Learning Research.
Scientific validation at scale
These foundations were progressively translated into robust and comprehensive models to create digital twins of patients. In 2023, a large independent validation study published in Nature Communications, based on nearly 5,000 patients, demonstrated the most accurate four-year cognitive decline prediction performance among 56 competing methods. The study showed that identifying fast progressors could reduce clinical trial sample sizes by 25 to 50%, depending on trial design.
From research to development
Qairnel was co-founded in 2023 to bring these validated innovations into clinical trial practice. Since then, we have been working with large pharmaceutical companies and biotechnology firms to deploy prognostic modeling approaches within active trials, improving the handling of patient heterogeneity and treatment effect estimation via the use our digital twins.
Trial-ready execution
Our models are delivered through an operational, trial-ready platform designed to minimize sponsor overhead. Blinded baseline data are securely shared, locked and versioned models are executed, and patient-level prognostic covariates are returned in formats directly usable within standard biostatistical frameworks. This workflow has been executed end-to-end in Phase 2 trials under strict timelines, with turnaround times of less than four weeks following database lock.
Beyond the trial
Experience in clinical trials highlighted a broader bottleneck: identifying the right patients early enough, particularly for pre-symptomatic and early-stage studies. To address this, we launched DocMemo in 2024, a pre-screening platform designed to detect memory complaints, assess risk, and orient individuals toward care or clinical trial participation. In 2025 alone, DocMemo profiled nearly 40,000 individuals across Europe and the United States and is actively supporting recruitment for Phase 2 and 3 trials in the US.
Mission & Vision
Our Vision
Detect early. Act early. Preserve brain health for life
We envision a future where neurological conditions are identified at their earliest stages, when interventions can be most effective, and where brain health is proactively preserved across the lifespan through timely, data-driven decisions.
Our Mission
Our mission is to improve brain health for all through early detection, precise assessment, and tailored care options — starting by democratizing access to clinical trials.
We develop and deploy AI solutions that enable earlier identification of at-risk individuals, more accurate characterization of disease trajectories, and better alignment between patients, care pathways, and clinical research opportunities.
Our Values
Sincerity
We value sincerity toward ourselves as much as toward others. We strive for clarity of intention and for conscious alignment between our motivations and our actions. We do not play roles or adopt postures. We choose to work with people and partners who are authentic, transparent, and grounded in reality.
Accountability & Autonomy
We take ownership of our actions and decisions and are accountable to the communities we belong to. This applies to our day-to-day work as well as the way we engage with our partners.
We also respect the autonomy of patients, honoring their choices and decisions at every stage.
Excellence & Ambition
We strive for the highest standards for ourselves and those we serve. We challenge the assumptions surrounding disease, care, and research, often the very reasons why innovation struggles to reach those who need it most.
We are always asking how we can improve, whether in product development or operational execution — to deliver meaningful impact for patients.
Thoughtfulness
In the face of the complexity and difficulty of our mission, we choose understanding over judgment. We critically examine ideas, hypotheses, and perspectives, wherever they come from, and make decisions thoughtfully and consciously.